China and US-headquartered biomedical firm Brii Bio has raised US$260 million from Sequoia Capital, Yunfeng Capital and others. ARCH Venture Partners, 6 Dimensions Capital, Boyu Capital, and Blue Pool Capital also participated in the round, according to the Brii Bio’s announcement. Brii Bio was founded in 2018 by a group of experienced medical professionals. Zhi Hong, its co-founder and CEO, is former head of GlaxoSmithKline’s (GSK) infectious diseases therapy unit. He led GSK’s efforts to cure HBV and HIV. The …

Chinese Biomed Firm Brii Bio Raises $260M From Sequoia Capital, Yunfeng Capital appeared first on China Money Network.